title: BORA-dependent PLK1 regulation: A new weapon for cancer therapy?
abstract: The mitotic kinase polo like kinase 1 (PLK1) is overexpressed in many cancers and its inhibition slows down proliferation and increases apoptosis in cancer cell lines. Understanding how PLK1 is activated is therefore crucial for the development of novel PLK1 inhibitors with anticancer properties. We recently identified a conserved regulatory loop leading to PLK1 activation that involves cyclin-dependent kinase 1 (CDK1).
authors.affiliation: Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva , Geneva, Switzerland.
authors.forename: Luca
authors.initials: L
authors.lastname: Cirillo
authors.affiliation: Jacques Monod Institute, UMR7592, Paris-Diderot University, Center National de la Recherche Scientifique , Paris, France.
authors.forename: Yann
authors.initials: Y
authors.lastname: Thomas
authors.affiliation: Jacques Monod Institute, UMR7592, Paris-Diderot University, Center National de la Recherche Scientifique , Paris, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Pintard
authors.affiliation: Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva , Geneva, Switzerland.
authors.forename: Monica
authors.initials: M
authors.lastname: Gotta
keywords: CDK1; Cell cycle; DNA damage; PLK1; cell division